The ophthalmology drugs market comprises of sale of the ophthalmology
drugs and other related services offered by different organization producing the
ophthalmology drugs for treating eyes associated diseases. The industry further
includes the establishment’s producing anti glaucoma drugs used for treating
glaucoma disease, and anti- inflammatory and tear stimulating drugs for dry eye
medications drugs, and other drugs for giving retinal disorders and other allergies.
According to study, “Ophthalmology Drugs Global Market Report 2019”
the key companies operating in the global ophthalmology drugs market are Bausch
& Lomb, Inc., Pfizer, Inc., Novartis AG, Regeneron, ALLERGAN PLC, Bayer AG,
Merck Sharp & Dohme Corp., Johnson & Johnson Services, Inc., Genentech,
Inc. and Santen Pharmaceutical Co., Ltd. The players are engaged in extensive
R&D activities developed the novel ophthalmic drugs for the treating of
various eye diseases and other disorders gaining a larger market share.
Based on drug class, ophthalmology
drugs market is segmented into antiglaucoma agents, anti-Vascular
Endothelial Growth Factor (anti-VEGF) agents, anti-inflammatory and
antiallergy. Anti-VEGF segment dominates the market owing to high adoption rate
and presence of global market players with extensive product portfolio. Based
on disease type, market is segmented into glaucoma, dry eye, retinal disorders,
eye infection, eye allergy, and uveitis. The retinal disorders segment is
expected to exhibit substantial growth rate due to increase in prevalence of
age-related macular degeneration and diabetic retinopathy during the forecast
period. Based on dosage form, market is segmented into eye solutions, capsules
and tablets, eye drops, ointments and gels. Eye drops segment holds major share
in market caused by ease of usage and high patient compliance.
Based on product type, market is segmented into Over-the-counter
(OTC) drugs and prescription.The prescription of drugs registered the largest
share as being more efficacious than the conventional drugs with fewer adverse
effects. In addition, based on route of administration insights, market is
segmented into local ocular, topical, and systemic route. The local ocular
route segment is further sub-segmented into intravitreal, retrobulbar,
subconjunctival, and intracameral. The intravitreal route segment is estimated
to be the largest segment being the highly efficient methods for delivering the drugs
over the posterior segment of the eye.
The ophthalmology drugs market is driven by increase in incidence
and prevalence of eye related disorders, followed by rise in funding from both
public and private research organizations, presence of strong emerging pipeline
drugs and increase in research & development (R&D) pertaining to the
development of novel drugs. However, loss of patent protection for blockbuster
drugs may impact the market.
Based on geography, the North-American region holds major share in
ophthalmology drugs market owing to high disease burden, growth in
technological advancements and rise in consumer awareness regarding the
advantages of ophthalmic drugs in the region. Whereas, the Asian-pacific and
European regions are estimated to witness higher growth rate due to improvement
in economic scenario, a large patient pool coupled with rise in disposable income
over the forecast period. In near future, it is predicted that the market will
be reached at high speed caused by growth in improvements in healthcare
infrastructure during the forecast period.
For More Information, refer to
below link:-
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
